Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects between the ages of 18 to 75 years, inclusive~* Confirmed diagnosis of Type 2 diabetes mellitus~* Meet required laboratory values at screening, including fasting plasma glucose less than 270 mg/dL~* Stable dose of metformin monotherapy greater than 1500 mg/day for at least 8 weeks~* Willing and able to provide written informed consent~* Willing and able to maintain consistent dietary, physical activity, and sleeping patterns throughout the study~Exclusion Criteria:~* History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes~* History of renal disease or clinically significant abnormal kidney function tests~* Presence of active hepatic disease or clinically significant abnormal liver function tests~* Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day 1~* History of clinically significant cardiac arrhythmias within one year of study Day 1~* Subjects with congestive heart failure~* Subjects with uncontrolled Stage III hypertension~* Triglycerides \>1000 mg/dL at Screening~* Known history of HIV or hepatitis C~* History of illicit drug or alcohol abuse with one year of study Day 1~* Have had 2 or more emergency room visits, doctor visits, or hospitalizations due to hypoglycemia within 6 months of study Day 1~* Use of any other investigational drug within 30 days of study Day 1~* Prior exposure to LX4211~* Use of any medication or herbal supplement for the purpose of weight loss~* Chronic use of any antidiabetic therapy other than metformin in the 3 months prior to study Day 1~* Use of corticosteroids within 2 weeks prior to study Day 1~* Major surgery within 6 months of study Day 1~* Subjects with any history of severe gastroparesis~* Inability or difficulty swallowing whole capsules or tablets~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None
- Treatment D (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).